Bcl2 inhibitor

DRUG CLASS:

Bcl2 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 2wk	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 positive	Gastric Cancer	HER-2 positive	Gastric Cancer	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 2wk	paclitaxel + minnelide Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks paclitaxel + minnelide Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
KRAS G12R	Pancreatic Ductal Adenocarcinoma	KRAS G12R	Pancreatic Ductal Adenocarcinoma	paclitaxel + gemcitabine Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks (New C3) paclitaxel + gemcitabine Sensitive : C3 ASCO-GI 2023 - 2wk	paclitaxel + gemcitabine Sensitive: C3 – Early Trials ASCO-GI 2023 - 2 weeks paclitaxel + gemcitabine Sensitive : C3 ASCO-GI 2023 - 2 weeks - (New C3)
BRCA wild-type	Ovarian Cancer	BRCA wild-type	Ovarian Cancer	carboplatin + paclitaxel Sensitive: C3 – Early Trials Int J Gynecol Cancer - 3 weeks (New C3) carboplatin + paclitaxel Sensitive : C3 Int J Gynecol Cancer - 3wk	carboplatin + paclitaxel Sensitive: C3 – Early Trials Int J Gynecol Cancer - 3 weeks carboplatin + paclitaxel Sensitive : C3 Int J Gynecol Cancer - 3 weeks - (New C3)
BCL2 underexpression	Ewing Sarcoma	BCL2 underexpression	Ewing Sarcoma	venetoclax Sensitive: D – Preclinical Biochem Pharmacol - 4 weeks (New D) venetoclax Sensitive : D Biochem Pharmacol - 4wk	venetoclax Sensitive: D – Preclinical Biochem Pharmacol - 4 weeks venetoclax Sensitive : D Biochem Pharmacol - 4 weeks - (New D)
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1	venetoclax + obinutuzumab Sensitive: A1 - Approval venetoclax + obinutuzumab Sensitive : A1
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	carboplatin + micellar paclitaxel Sensitive: A1 - Approval carboplatin + micellar paclitaxel Sensitive : A1	carboplatin + micellar paclitaxel Sensitive: A1 - Approval carboplatin + micellar paclitaxel Sensitive : A1
No biomarker	Fallopian Tube Cancer	No biomarker	Fallopian Tube Cancer	carboplatin + micellar paclitaxel Sensitive: A1 - Approval carboplatin + micellar paclitaxel Sensitive : A1	carboplatin + micellar paclitaxel Sensitive: A1 - Approval carboplatin + micellar paclitaxel Sensitive : A1
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	venetoclax + rituximab Sensitive: A1 - Approval venetoclax + rituximab Sensitive : A1	venetoclax + rituximab Sensitive: A1 - Approval venetoclax + rituximab Sensitive : A1
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1
No biomarker	Ovarian Cancer	No biomarker	Ovarian Cancer	carboplatin + micellar paclitaxel Sensitive: A1 - Approval carboplatin + micellar paclitaxel Sensitive : A1	carboplatin + micellar paclitaxel Sensitive: A1 - Approval carboplatin + micellar paclitaxel Sensitive : A1
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	carboplatin + albumin-bound paclitaxel Sensitive: A1 - Approval carboplatin + albumin-bound paclitaxel Sensitive : A1	carboplatin + albumin-bound paclitaxel Sensitive: A1 - Approval carboplatin + albumin-bound paclitaxel Sensitive : A1
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval gemcitabine + albumin-bound paclitaxel Sensitive : A1	gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval gemcitabine + albumin-bound paclitaxel Sensitive : A1
No biomarker	Breast Cancer	No biomarker	Breast Cancer	albumin-bound paclitaxel Sensitive: A1 - Approval albumin-bound paclitaxel Sensitive : A1	albumin-bound paclitaxel Sensitive: A1 - Approval albumin-bound paclitaxel Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1
No biomarker	Small Lymphocytic Lymphoma	No biomarker	Small Lymphocytic Lymphoma	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1	venetoclax Sensitive: A1 - Approval venetoclax Sensitive : A1
No biomarker	Chronic Lymphocytic Leukemia	No biomarker	Chronic Lymphocytic Leukemia	venetoclax + ibrutinib Sensitive: A1 - Approval venetoclax + ibrutinib Sensitive : A1	venetoclax + ibrutinib Sensitive: A1 - Approval venetoclax + ibrutinib Sensitive : A1
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + paclitaxel + 5-fluorouracil Sensitive : A2	cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + paclitaxel + 5-fluorouracil Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2
No biomarker	Oral Cancer	No biomarker	Oral Cancer	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2	cisplatin + paclitaxel Sensitive: A2 - Guideline cisplatin + paclitaxel Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2
No biomarker	Oropharyngeal Cancer	No biomarker	Oropharyngeal Cancer	cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + paclitaxel + 5-fluorouracil Sensitive : A2	cisplatin + paclitaxel + 5-fluorouracil Sensitive: A2 - Guideline cisplatin + paclitaxel + 5-fluorouracil Sensitive : A2
No biomarker	Nasopharyngeal Carcinoma	No biomarker	Nasopharyngeal Carcinoma	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2
No biomarker	Small Intestinal Carcinoma	No biomarker	Small Intestinal Carcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2
No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	paclitaxel + topotecan Sensitive: A2 - Guideline paclitaxel + topotecan Sensitive : A2	paclitaxel + topotecan Sensitive: A2 - Guideline paclitaxel + topotecan Sensitive : A2
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
IDH1 mutation	Acute Myelogenous Leukemia	IDH1 mutation	Acute Myelogenous Leukemia	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2	venetoclax Sensitive: A2 - Guideline venetoclax Sensitive : A2
TP53 mutation	Chronic Lymphocytic Leukemia	TP53 mutation	Chronic Lymphocytic Leukemia	venetoclax + rituximab Sensitive: A2 - Guideline venetoclax + rituximab Sensitive : A2	venetoclax + rituximab Sensitive: A2 - Guideline venetoclax + rituximab Sensitive : A2
Chr del(17p)	Chronic Lymphocytic Leukemia	Chr del(17p)	Chronic Lymphocytic Leukemia	venetoclax + rituximab Sensitive: A2 - Guideline venetoclax + rituximab Sensitive : A2	venetoclax + rituximab Sensitive: A2 - Guideline venetoclax + rituximab Sensitive : A2
No biomarker	Peritoneal Cancer	No biomarker	Peritoneal Cancer	carboplatin + albumin-bound paclitaxel Sensitive: A2 - Guideline carboplatin + albumin-bound paclitaxel Sensitive : A2	carboplatin + albumin-bound paclitaxel Sensitive: A2 - Guideline carboplatin + albumin-bound paclitaxel Sensitive : A2

Bcl2 inhibitor

Bcl2 inhibitor

Associations(634)

Associations
(634)